pHalcon-EE: VOQUEZNA demonstrated a safety profile comparable to a PPI1,*
| In the
2- to 8-week healing phase: adverse reactions reported in ≥2% of adult patients in the voquezna arm in all grades of erosive gerd | ||
|---|---|---|
| Adverse Reactions | VOQUEZNA 20 mg † | Lansoprazole 30 mg † |
| Gastritis‡ | 3% | 2% |
| Diarrhea‡ | 2% | 3% |
| Abdominal distension | 2% | 1% |
| Abdominal pain‡ | 2% | 1% |
| Nausea | 2% | 1% |
| IN THE 24-WEEK MAINTENANCE PHASE: ADVERSE REACTIONS REPORTED IN ≥3% OF ADULT PATIENTS IN THE VOQUEZNA ARM IN ALL GRADES OF EROSIVE GERD | ||
|---|---|---|
| Adverse Reactions | VOQUEZNA 10 mg † | Lansoprazole 15 mg † |
| Gastritis‡ | 6% | 3% |
| Abdominal pain‡ | 4% | 2% |
| Dyspepsia | 4% | 3% |
| Hypertension‡ | 3% | 2% |
| Urinary tract infection | 3% | 2% |
*The trial was not designed to support comparative claims for VOQUEZNA for the adverse reactions reported in the tables above.1
†Represents safety population.
‡Represents a grouped term and includes related terms.1